Hydrafacial Results Presentation Deck
Q2 2023 balance sheet highlights
Cash and cash
equivalents
Warrants
Convertible
debt
Revolving
credit facility
Shares
outstanding
13
→ Approximately $549.7 million cash and cash equivalents on balance sheet
(+$17.4 million vs Q1 2023)
→ Approximately 7 million private warrants outstanding
→ $750 million 1.25% convertible notes due 2026
→ Use of proceeds: capped call transaction, potential future acquisitions, working capital
expenditures, and general corporate purposes
→ Conversion price of $31.76; capped call agreement provides dilution protection up to
$47.94
$50 million Senior Secured Credit Facility remains undrawn; current undrawn
commitment fee of 25 bps
◆ Allows flexibility for future M&A; ex-US operations unencumbered; convertible debt
excluded from covenants
Approximately 132.9 million current shares outstanding
BEAUTYHEALTH™View entire presentation